pharma

CONFERENCE

...see all

3rd Annual Biomarkers Conference

An essential addition from discovery to approval in clinical development

23rd - 24th March 2010, BSG Conference Centre, London, UK

Download brochure Products

Background Info
Day 1
Day 2
Partners
Past Papers

Associate Sponsors

Media Partners

Background Info

Key Speakers
• James Weatherall, Global Lead, Biomedical Informatics, AstraZeneca
• David W. Moskowitz, Chairman, CEO & Chief Medical Officer, GenoMed
• Fabio Magrini, Director, Inflammation and Autoimmunity, MedImmune
• Hassan Rahmoune, Head of Translational Medicine & Discovery Biomarkers, University of Cambridge/Psynova
• Christian Rohlff, CEO, Oxford BioTherapeutics
• Richard Kennedy, Vice President of Translational Research and Development, Almac group
• Stéphane Lucchini, Business Manager, Biovays
• Patricia Hurley,Head of Project Management & Head of Biomarkers Division, ERA Consulting UK
• Peter Duncan, Director of Business Development, Clinical Diagnostics, Definiens
• Huw Davies, Director Business Development, Pronota
• Eddie Blair, Director, Integrated Medicines
• Niro Ramachandran, R&D Manager, Life Technologies
• Ian Pike, Chief Operating Officer, Proteome Sciences
• Ehud Hauben, Business Development Manager, Leiden University Medical Centre

Pharmaceutical and biotech companies are looking for new ways to increase the efficiency of drug discovery process while minimising costs and time for approvals. Biomarkers are fast becoming an essential part of clinical development from discovery to approval. According to industry research, the global biomarker market is estimated to be $20.5 billion by 2014, growing at a CAGR of 19.7 %.

Additionally, the use of proteomics in biomarker testing and identification has boosted the services for biomarkers. A large number of companies now have commercialised biomarker tests employing a variety of technologies. However, there are several barriers and challenges that must be overcome behind these technologies.

Visiongain is proud to present its 3rd Annual Biomarker Conference, which will be held in London UK on 23-24 March 2010.This conference will enable you to identify and overcome challenges on how to incorporate biomarkers into your discovery programs as well as highlighting new technologies and strategies to improved prevention and care approaches.

Conference Main Themes:

• Use of academic laboratories in clinical development to foster collaborative research
• Biomarkers in Translational Medicine
• Integration of a companion diagnostic strategy into oncology drug development
• How biomarkers, personalized medicines, and pharmaceutical will interact and create value for patients?
• Mass Spectrometry in Biomarker Discovery
• New results in functional genomics
• Anti-inflammatory efficacy of drug substances using biomarkers of inflammation
• Biomarker assay development and validation in cancer
• Role of biomarkers in the development of personalized medicine
• Biomarkers in a clinical perspective
• Development in protein array technologies for biomarker discovery

Who should attend?

VPs, Directors, Heads and Managers of:-
• Biomarker Development Programmes
• Clinical Pharmacology
• Clinical Research
• Drug Discovery and Development
• Alliance Management
• Safety Assessment
• Assay Development
• Proteomics/ Genomics Programmes
• Regulatory Affairs
• Translational Medicine
• Oncology
• CNS
• Inflammation and Immunology
• Biological Sciences
• Marketing
• Product
• Diagnostics
• Bioanalysis
• Pharmacokinetics & Drug Metabolism
• Genomics Business Development
• Strategic Alliances
• Cellular & Molecular Dev
• Clinical Discovery Technologies
• Pharmacogenomics & Human Genetics
• Discovery Research
• Bioengineering

Day 1

Day One, Tuesday 23rd March 2010, London, UK

09:00 Registration and refreshments

09:30 Chair’s opening remarks

Eddie Blair
Director
Integrated Medicines

09:40 Biomarkers in translational medicine
• Introduction
• Bio-sampling
• Lessons learned “Biomarkers discovery and clinical protocols’’
• Case study - functional studies and study design
• Summary

Hassan Rahmoune
Head of Translational Medicine & Discovery Biomarkers
University of Cambridge / Psynova

10:20 Providing integrated protein biomarker solutions for clinical trials

Christian Rohlff
CEO
Oxford BioTherapeutics

11:00 Morning refreshment & networking session

11:20 The application of biomedical informatics to biomarker development in the clinical setting
• Background to Biomedical Informatics in clinical drug development
• Modeling and Simulation for personalised Healthcare
• Integrating modelling and simulation into a clinical program
• Support for biomarker discovery, development and validation via data mining
• Case studies for both efficacy and safety

James Weatherall
Global Lead, Biomedical Informatics
AstraZeneca

12:00 Protein array technologies for biomarker discovery
• How to design a biomarker discovery study.
• Technology requirements for discovering biomarkers
• Types of protein arrays and their use in biomarker discovery
• Development and use of ProtoArrays

Niro Ramachandran
R&D Manager
Life Technologies

12:40 Lunch

13:40 Combining open platform and targeted approaches for protein biomarker discovery and development
• Analytical requirements for plasma protein biomarker discovery
• Study design and technology considerations for discovery and verification stages
• Bridging the gap between discovery and clinical implementation
• Case study: discovery and validation of novel plasma protein biomarkers for the diagnosis and management of heart failure

Huw Davies
Director, Business Development
Pronota

14:20 How biomarkers and pharmaceuticals interact as personalised medicines to create value for patients?
• Diagnostic value as leverage in companion diagnostic relationships
• Relative value of predictive and prognostic markers
• The role of stakeholder perceptions in the value proposition
• The cash value and market for companion pharmaceuticals and diagnostics

Eddie Blair
Director
Integrated Medicines

15:00 Afternoon refreshments & networking session

15:20 Integrating your biomarker into drug development: The importance of the EMEA/FDA qualification procedures
• Use of biomarkers from the pre-clinical and clinical drug development process; Case studies
• The importance of seeking agency input on the validity of your biomarker
• New biomarker qualification procedures in Europe and the US
• Why does going through the qualification procedure make sense?

Patricia Hurley
Head of Project Management & Head of Biomarkers Division
ERA Consulting UK

16:00 Chair’s closing remarks

16:10 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting

Day 2

Day Two, Wednesday 24th March 2010, London, UK

09:00 Registration and refreshments

09:30 Chair’s opening remarks

09:40 Translational biomarkers – From preclinical to clinical acceptance

Christine Grier
International Sales Executive
Argutus Medical LTD

10:20 Rapid MS assays for biomarker discovery, validation and routine use in Alzheimer’s disease
• Methodology for rapid progression from biomarker discovery to targeted assays
• Tau phosphorylation screening assay to assist drug development
• Multiplex blood biomarker panel for diagnosis and prognosis of Alzheimer’s disease

Ian Pike
Chief Operating Officer
Proteome Sciences

10:40 Biomarker assay development and validation in cancer
• Types of biomarkers used in cancer and available technologies
• Potential sources of tissue from patients
• The use of FFPE archived tissue for biomarker discovery and delivery
• Examples of prognostic and predictive test development for personalised cancer management
• Issues around test validation

Dr Peter Kerr
Head of Product Development
Almac

11:20 Morning refreshment & networking session

11:40 Using experimental medicine to mitigate risk in early CNS drug development

Gerry Dawson
Chief Scientific Officer
P1vital

12:20 Biomarkers of immune-activation and immune-tolerance
• Biomarkers facilitate decision making in drug development by enabling informed clinical trial design (e.g. dose selection, duration and size)
• A balancing act between limitations of clinical trial settings (blood volume, onsite methodology and infrastructure) vs. specificity and quality of measurements requires careful planning and prioritization
• In immunomodulatory treatments for immune-mediated diseases, infectious diseases and cancer (e.g. active and passive vaccines) biomarkers are essential readouts for safety, MOA, PD and PK
• Correlation between proteomic/genomic markers and functional readouts in specific immune-cell-subsets can identify and confirm biomarkers in a relatively small sample size

Ehud Hauben
Business Development Manager
Leiden University Medical Centre

13:00 Lunch

14:00 Prognostic tumor markers for breast cancer
• The MUC-1 gene products
• CEA, CA125
• Cytokeratins
• Cytokines
• Role of all these molecules in initial diagnosis, prognosis, response to therapy assessment, early detection of metastases in breast cancer

Vivian Barak
Head, Immunology & Tumor Diagnosis Lab., Oncology Dept
Hadassah - Hebrew University Medical Center

14:40 Strengthening your pipeline: collaborative partnerships
• Promises and challenges of biomarkers
• Commercial opportunities for biomarkers
• Role of partners in biomarker assay development
• Harnessing human capital: expertise & experience
• Maximising drug success: innovating forward

Stéphane Lucchini
Business Manager
Biovays

15:20 Chair’s closing remarks

15:30 End of conference

Partners

Associate Sponsors:

Randox Pharma Services
- Supporting your clinical trials
In recognition of the vital role biomarkers play in drug development programmes, Randox Pharma Services offers a comprehensive range of technologies and solutions, allowing Pharma R&D to become more efficient, cost effective and safer. Biochip Array Technology, a revolutionary multiplexing technology, enables multiple biomarker results from a single sample. Over 120 enzymatic, substrate and Immunoturbidimetric assays are available for use on our range of world class clinical chemistry analysers while our QC range provides essential performance checks and traceability. And if you require a tailor made solution - we can provide custom assay design, development and manufacturing. Randox Pharma Solutions support every stage of the clinical trial process. For further information, please visit www.randox.com

Proteome Sciences plc
PS Biomarker Services™ offers full service biomarker contract research for fast, flexible and cost-effective workflows for proteomic and peptidomic biomarker discovery, validation and implementation. Tandem Mass Tag® (TMT®) technology allows simultaneous analysis of up to six samples and universal reference materials to improve sensitivity and precision of biomarker discovery, and seamless transition from discovery into targeted multiplex assays for up to 30-50 candidate biomarkers for validation. Rapid MS assays have been developed for plasma biomarkers of Alzheimer's disease and for measuring tau phosphorylation status in AD models. These services are available for outsourcing from our ISO 9001:2008 facility in Frankfurt. For further information, please visit www.proteomics.com

Media Partners:

PharmiWeb.com
PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US. For further information please email: corporate@pharmiweb.com

BIOTECHNOLOGY EUROPE
BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the main goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities. For further information please visit www.biotechnology-europe.com

Future Pharmaceuticals
Future Pharmaceuticals has forged powerful relationships with key industry leaders to provide a platform for successful brand recognition, and for senior decision-makers to have the means to procure and plan implementation strategies based on the topics covered. Positioned to be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries' top issues and the solutions top-tier vendors can provide. For further information, please visit www.futurepharmaus.com

InPharm
InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. For further information please visit: www.In-Pharm.com

Pharma Connections Worldwide
Pharma Connections Worldwide® is the leading professional business networking website focused in the Pharmaceutical, Biotechnology and Life Sciences research industry. Our goal is to provide a conduit for delivery of premiere content coupled with the right clientele in order to facilitate business development opportunities among industry professionals responsible for making key decisions in a global marketplace. For further information please visit www.pharmaconnections.com

Enquiries

If you would like more information on the range of sponsorship or exhibition possibilities for visiongain's 3rd Annual Biomarkers Conference, please contact:
Ronald Magali, +44 (0)20 7549 9934
ronald.magali@visiongainglobal.com
Christopher Clegg, +44 (0)20 7549 9943
christopher.clegg@visiongainglobal.com

Past Papers

Speaker presentations are free to delegates. If you are unable to attend the event, the presentations are published two weeks after the event and are available to purchase.

Buy Now